CorMedix Inc. is a pharmaceutical company that develops and seeks to commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as Cardiorenal disease. Specifically, their goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications – in effect, "Treating the kidney to treat the heart." Cormedix therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy.


CorMedix is a featured company in the ProActive News Room. Click here to learn more.

CorMedix Management:

John C. Houghton BSc.
President/CEO

John is a rare business executive, whose 20 years of experience has spanned global strategic and affiliate tactical roles covering the full product life-cycle from research through generics, including drugs, biologicals and devices.

Before joining CorMedix, John established the global sales and marketing infrastructure for the Biotech division of Stryker. Prior to Stryker Biotech, John worked for Aventis (and predecessor companies) for more than 14 years.

Mark T. Houser, M.D., MBA
Chief Medical Officer

As an experienced academic and clinical nephrologist, with a strong clinical research, basic science, and management background, Mark has a unique skill set that well suits CorMedix's cardiorenal aspirations.

During his tenure at Johnson & Johnson (OrthoBiotech) Mark had diverse responsibilities including: Leading clinical development projects in oncology and critical care, Leading business development projects primarily focused on cardiorenal projects; 50+ projects accessed, Internal nephrology consultant to the J&J family of companies, Regional medical affairs management for Procrit.

Brian Lenz, CPA, MBA
Chief Financial Officer

Brian has over 15 years of financial and operational experience in addition to significant capital raising, merger and acquisition and other strategic activities.

Prior to joining CorMedix, Brian was the Chief Financial Officer and Treasurer at Arno Therapeutics and prior to that served the same roles at VioQuest Pharmaceuticals, Inc.

Prior to VioQuest, Brian was the controller of Smiths Detection Group where he was responsible for corporate and operational financial reporting and consolidation of its international operations, in addition to being responsible for the information technology and human resources functions. Brian started his career as a senior auditor with KPMG, LLP. Brian is a certified public accountant licensed in the State of New Jersey, and a member of the CFO advisory committee of BIONJ.